Table of Contents
The FDA’s position on CBD is narrower than most consumers realize. The agency has approved exactly one CBD product — Epidiolex, a prescription oral solution for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex (approved June 2018, expanded 2020). Every other CBD product on the market is unapproved. The FDA’s position is that CBD may not lawfully be added to food sold in interstate commerce or marketed as a dietary supplement, because CBD is the active ingredient in an approved drug and was the subject of substantial clinical investigations before it was marketed as a food or supplement (the “drug exclusion” provisions, 21 U.S.C. §331(ll) and §321(ff)(3)(B)). On January 26, 2023, the FDA announced that existing regulatory frameworks for foods and supplements are “not appropriate” for CBD and called on Congress to create a new pathway; as of September 2026, Congress has not created one. The FDA’s CBD regulatory position explains the full mechanism.
What the FDA has and has not done
| Action | Status |
|---|---|
| Approved CBD drug | Epidiolex only (3 seizure disorders) |
| CBD in food/supplements | Barred under current law |
| Warning letters | Issued repeatedly, including 2025, for disease claims |
| New regulatory pathway | Requested from Congress (Jan 2023); none enacted |
| Federal hemp definition | Rewritten by P.L. 119-37; total-THC + 0.4 mg cap from Dec 11, 2026 |
The FDA has also raised specific safety concerns: liver injury, drowsiness, diarrhea, appetite changes, and drug interactions (CBD inhibits CYP3A4/CYP2C19). Quality control is a documented problem — independent testing has repeatedly found mislabeled products. See our hemp product mislabeling study and the NCCIH cannabis evidence summary. See our CBD gummies guide and our CBD isolate guide.
What consumers should do
Check for third-party testing, clear labeling, and no disease claims — and consult a healthcare provider before use, especially if you take other medications. See our CBD retail guide and our CBD dabs and fine hemp dabs.
Frequently asked questions
What is the FDA’s current stance on CBD products?
Only Epidiolex is approved; CBD may not lawfully be added to food or sold as a supplement; the FDA wants a new regulatory pathway from Congress.
Are CBD products approved by the FDA?
No retail CBD product is FDA-approved. Epidiolex, a prescription seizure drug, is the only approved CBD product.
What regulations does the FDA have for CBD?
The drug-exclusion rules bar CBD in food and supplements; the FDA enforces against disease claims via warning letters; no federal quality standards exist for retail CBD.
Has the FDA warned about CBD safety?
Yes — liver injury, drowsiness, diarrhea, appetite changes, drug interactions, and widespread mislabeling.
Will CBD regulation change?
P.L. 119-37 rewrites the federal hemp definition from December 11, 2026; a dedicated CBD regulatory pathway still awaits Congress.
Browse the CBD Guides hub.
Affiliate Disclosure
The CakeHeights Editorial Team is committed to providing accurate, research-backed information about cannabis and hemp products. Some links on this page are affiliate links, meaning we may earn a commission at no extra cost to you if you make a purchase through them. Our recommendations are based on independent research, testing, and analysis. We only promote products we believe offer genuine value to our readers. Learn more →
Leave a Reply